According to Dr. Marc Van Eden, V.P. of Business Development at Zymo Research, “Making genome-wide epigenetic analyses available to all researchers will mark the beginning of a new era in epi-biomarker discovery and validation that will aid in the diagnostics and prognostics of human diseases. Epigenetics research will also facilitate advancements in personalized medicine and companion diagnostics to optimize the efficiency of individualized drug treatment. We may begin to ask how things like the environment and our diet affect who we are and who we will likely become.” With genome-wide and targeted epigenetic sequencing services, companies like Zymo Research make profiling the epigenome of patients a reality. Such advancements will become crucial in furthering our understanding of science and medicine and should have a significant impact on how we diagnose and treat human diseases in the future.
For more information or to inquire about the epigenetic services, please contact Zymo Research at:
Tel: (949) 679-1190
Toll free: (888) 882-9682
Zymo Research Corporation is a privately held biotechnology company located in Irvine, California that provides the highest quality epigenetics products and services, in addition to DNA and RNA purification products. The philosophy of the company is to provide the most innovative, quality products, while ensuring they are both simple and reliable to use.
Read the full story at http://www.prweb.com/releases/2013/3/prweb10
Copyright©2012 Vocus, Inc.
All rights reserved